Anti-PD1 induced psoriasis

Published: 28 September 2020| Version 1 | DOI: 10.17632/m7w8sszs6y.1
Contributor:
Vasiliki Nikolaou

Description

This table includes data from 115 patients who developed psoriasis as an immune related adverse event to anti-PD-1/PDL1 agents. Psoriasis treatment outcomes of both topical and systemic agents used are presented

Files

Categories

Dermatology, Psoriasis, Immune Checkpoint Blockade

Licence